Search a ticker

Categories
Featured Health Care Stocks

Best Health Care Stocks To Watch This Month

health care stocks

Are These 2 Best Health Care Stocks On Your Watchlist This Month?

Health care stocks have been some of the best-performing stocks since the market bottomed out in March. With a lot of coronavirus developments in play, this sector is racing to come up with a vaccine or treatment. The world desperately needs treatments or a cure for this dangerous virus. As companies continue to make developments, investors are watching the top health care stocks closely.

Given the market’s current volatility within the health care space, it will be interesting to see which health care stocks end up finishing first in the race to develop the first treatment or vaccine for mass distribution. Let’s take a look at some of the best health care stocks to watch in June.

Read More

Best Health Care Stocks To Watch #1: Eli Lilly and Company

The first company on this list of healthcare stocks is Eli Lilly and Company (LLY stock report). This past week Eli Lilly started phase 1 study on a potential antibody therapy to help treat coronavirus.

The company reported that the first patients have been dosed in a phase 1 study on LY-CoV555, its lead antibody therapy candidate in partnership with AbCellera, a private biotech company. The study will evaluate the safety and tolerability in patients that are hospitalized with Covid-19. Results from this study are anticipated to be released in June.

Year to date LLY stock has seen a price change of 12.58%. This top healthcare stock to watch is a prime example of seeing results on the market after news about coronavirus trials. Will Eli Lilly be the first company to have a feasible coronavirus vaccine?

[Read More] 3 Best Cybersecurity Stocks To Watch In June 2020

Healthcare Stock To Watch #2: Myovant Sciences Ltd. (MYOV)

Myovant Sciences (MYOV stock report) is a clinical-stage biopharmaceutical company. Myovant has a primary focus on women’s health diseases. Recently, Myovant submitted a drug application to the FDA for a medication treating women with heavy menstrual bleeding associated with uterine fibroids. They did multiple Phase III studies and showed an 84.3% improvement with their medicine.

CEO of Myovant, Lynn Seely, said, “An estimated five million women in the U.S. suffer from symptoms of uterine fibroids, which may include heavy menstrual bleeding, pain, and anemia – yet effective non-invasive treatment options are very limited. If approved, we hope to redefine care for these women with relugolix combination tablet, a potential new treatment that demonstrated a predictable and clinically-meaningful reduction in menstrual blood loss while maintaining bone health in the Phase 3 LIBERTY program.”

After the reporting of this news, MYOV stock price surged. On May 29th, MYOV stock price was trading at $12.23 a share. After the release of this news shares hiked to $17.40 a share, reaching a high of $18.76. This 42.27% increase in stock price is very significant for the company.

Do you think that Myovant will continue to move higher if this drug is approved?

[Read More] 3 Health Care Stocks To Consider For Your Portfolio

Bottom Line

Though the COVID-19 crisis is affecting health care stocks in many ways as stated above. This doesn’t mean companies unrelated to Covid-19 like Myovant aren’t able to perform well too. The fact is everyone needs health care, or they will need it some point in their lives. If there’s something that everyone needs, there lies a potentially great opportunity for investors.

By Jonathan Phillip

Jonathan Phillip is an up and coming financial contributor in the stock market today. He's found a strong niche in writing about true growth industries. His main focus for the last 5 years has been on the cannabis industry and marijuana stocks. He is one of the top contributors to cannabis media outlets like MarijuanaStocks.com. He also is head of social media management for StockMarket.com.

Since an early age, Jonathan has been an active member of the cannabis culture. Coming from Miami, Florida, he's been able to identify emerging trends in the space including the emergence of cannabis derivatives, vapes, e-liquids, wax, and more. His ability to identify emerging niches has afforded him the ability to source valuable information from top industry names.

Jonathan has also managed to build a strong social media presence for companies. He has worked with hundreds of public companies to develop a digital presence. As an active blogger and social media influencer, his focus is on lifestyle segments of the market. You can find Jonathan reporting on anything from industry conferences and investor events to corporate disclosures and cannabis market movers.

Since the early days of marijuana companies going public, Jonathan has made it a point to find information before the crowd. The main target of his writing is on undiscovered or under-researched companies that could hold true, lasting market potential. Through his research, Jonathan has managed to be one of the early writers to identify the opportunity of cannabis over other things like alcohol and he was one of the first reporters to cover the multi-billion dollar deals that materialized in 2017 and 2018. He has also covered the emergence of multi-state operators in the U.S. after Canada paved the way in late 2018 and 2019 for legalization in North America.

Jonathan is also an active member of the underground hip-hop scene. He has worked with some of the biggest names in the rap community while also gaining valuable insight from top producers and business moguls focused on moving brands forward. In his free time, Jonathan builds social communities and continues to hone his skills as a leading financial writer.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments